NCT05521789 Erector Spinae Block for Thoracic Surgery
| NCT ID | NCT05521789 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | George Washington University |
| Condition | Pulmonary Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2022-07-22 |
| Primary Completion | 2026-12-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 70 participants in total. It began in 2022-07-22 with a primary completion date of 2026-12-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.
Eligibility Criteria
Inclusion Criteria: * pulmonary resection * 18\<age\<90 Exclusion Criteria: * pleurodesis * decortication * emergent surgery * local anesthetic allergy * intraoperative complication (inadvertent hemorrhage or conversion to open surgery) * bilateral pulmonary resection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05521789 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Pulmonary Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05521789 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05521789 currently recruiting?
Yes, NCT05521789 is actively recruiting participants. Contact the research team at eshaykhinurov@mfa.gwu.edu for enrollment information.
Where is the NCT05521789 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT05521789 clinical trial?
NCT05521789 is sponsored by George Washington University. The trial plans to enroll 70 participants.